Expression of hypoxia-inducible factor (HIF-1α), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 3003-3010

  Okada, Koichiro ^a   Osaki, Mitsuhiko ^a   Araki, Kunio ^a   Ishiguro, Kiyosuke ^a   Ito, Hisao ^a   Ohgi, Shigetsugu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Breast ductal carcinoma; HIF 1 ; VEGF C; VEGF D

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN C; VASCULOTROPIN D;

ANGIOGENESIS; ARTICLE; BREAST EPITHELIUM; BREAST FIBROADENOMA; CANCER STAGING; CARCINOGENESIS; CARCINOMA IN SITU; CELL HYPOXIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR NECROSIS;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL; FEMALE; FIBROADENOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 22944466403     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hockel M and Vaupel P: Tumour hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001.
2. Ellis LM and Fidler IJ: Angiogenesis and metastasis. Eur J Cancer 32A: 2451-2460, 1996.
3. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
4. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, prosnitz LR and Dewhirst MW: Tumour oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941-943, 1996.
5. Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88: 1474-1480, 2000.
6. Semenza GL: Hypoxia, clonal selection, and the role of HIF-1 in tumour progression. Crit Rev Biochem Mol Biol 35: 71-103, 2000.
7. 2 homeostasis by hypoxia-inducible factor 1alpha. Gene Dev 12: 149-162, 1998.
8. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998.
9. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
10. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL and Koukourakis MI: Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95: 1055-1063, 2002.
11. Folkman J: Proceedings: tumour angiogenesis factor. Cancer Res 34: 2109-2113, 1974.
12. Folkman J, Merler E, Abernathy C and Williams G: Isolation of a tumour factor responsible for angiogenesis. J Exp Med 133: 275-288, 1971.
13. Brown LF, Detmer M, claffey K, Nagy JA, Feng D, Dvorak AM and Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79: 233-269, 1997.
14. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP and Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vivo expression of VEGF by human prostate cancer cells. J Urol 157: 2329-2333, 1997.
15. Takahashi Y, Kitadai Y, Bucana CD, Clearly KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968, 1995.
16. Bancher-Todesca D, Obermair A, Bilgi S, Kohlberger P, Kainz C, Breitenecker G, Leodolter S and Gitsch G: Angiogenesis in vulvar intraepithelial neoplasia. Gynecol Oncol 64: 496-500, 1997.
17. Abu-Jawdeh GM, Faix JD, Niloff JT, Tognazzi K, Manseau E, Dvorak HF and Brown LF: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 74: 1105-1115, 1996.
18. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL and Schnitt SJ: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26: 86-91, 1995.
19. Clauss M: Molecular biology of the VEGF and the VEGF receptor family. Sem Thromb Hemost 26: 561-569, 2000.
20. Kishimoto K, Sasaki A, Yoshihara Y, Mese H, Tsukamoto G and Matsumura T: Expression of vascular endothelial growth factor-C predicts regional lymph node metastasis in early oral squamous cell carcinoma. Oral Oncol 39: 391-396, 2003.
21. Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo A and Burian M: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 25: 464-474, 2003.
22. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H and Achen MG: VEGF-D promotes the metastatic spread of tumour cells via the lymphatics. Nat Med 7: 186-191, 2001.
23. Scavelli C, Weber E, Agliano M, Cirulli T, Nico B, Vacca A and Ribatti D: Lymphatics at the crossroads of angiogenesis and lymphangiogenesis. J Anat 204: 433-449, 2004.
24. Takahashi M, Yoshimoto T and Kubo H: Molecular mechanisms of lymphangiogenesis. Int J Hematol 80: 29-34, 2004.
25. Choi WW, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, Cohen C and Young AN: Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol (in press).
26. The Japanese Breast Society. General Rules for Clinical and Pathological Recording of Breast Cancer. 14th ed., Kanehara shuppan, Tokyo, 2000.
27. Silverstein MJ, Lagions MD, Craig PH, Waisman JR, Lewinsky BS, Calbuurn WJ and Poller DN: A prognostic index for ductal carcinoma in situ of the breast. Cancer 77: 2189-2192, 1996.
28. Elson CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a larger study with long-term follow up. Histopathology 19: 403-410,1991.
29. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y and Fujii-Kuriyama Y: A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94: 4273-4278, 1997.
30. Currie MJ, Hanrahan V, Gunningham SP, Morrin HR, Frampton C, Han C, Robinson BA and Fox SB: Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1α) and the HIF-1α target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J Clin Pathol 57: 829-834, 2004.
31. Tomes L, Emberley E, Niu Y, Troup S, Pastorek J, Strange K, Harris A and Watson PH: Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 81: 61-69, 2003.
32. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ and van der Wall E: Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97: 1573-1581, 2003.
33. Hyder SM, Nawaz Z, Chiappetta C and Stancel GM: Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60: 3183-3190, 2000.
34. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholova I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K and Yla-Herttuala S: VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 92: 1098-1106, 2003.
35. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar M: Induction of tumour lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192-198, 2001.
36. Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K and Harkonen PL: VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumours. Int J Cancer 98: 946-951, 2002.
37. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orei L, Alitalo K, Christofori G and Pepper MS: Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672-682, 2001.
38. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T and Alitalo K: Suppression of tumour lymph-angiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94: 819-825, 2002.
39. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R and Alitalo K: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154: 1381-1390, 1999.
40. Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, Tomarev S, Wilting J and Sleeman JP: Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumours and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 63: 713-722, 2003.
41. Simak A and Coombes RC: Endocrine-responsive breast cancer and strategies for combatting resistance. Nat Rev Cancer 2: 101-115, 2002.